RPL17 and esophageal squamous cell carcinoma: PD-L1 positive tumors, which generally have abundant TIICs including PD-1+ immune cells, may define a subset of ESCC patients who are potential candidates for anti-PD-1 or anti-PD-L1 antibody therapy.